egrifta sv
(tesamorelin)Theratechnologies Inc.
Usage: EGRIFTA SV is indicated for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. It is not intended for weight loss management or improving adherence to anti-retroviral therapies. Long-term cardiovascular safety remains unestablished, warranting caution in treatment continuation if visceral adipose tissue does not reduce.